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Abstract 
Sleep abnormalities are associated with acute and chronic use of addictive substances. Although sleep complaints 
associated with use and abstinence from addictive substances are widely recognized, familiarity with the underlying 
sleep abnormalities is often lacking, despite evidence that these sleep abnormalities may be recalcitrant and impede 
good outcomes. Substantial research has now characterized the abnormalities associated with acute and chronic use 
of alcohol, cannabis, cocaine, and opiates. This review summarizes this research and discusses the clinical implications 
of sleep abnormalities in the treatment of substance use disorders.
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Background
Sleep problems are commonly associated with drug and 
alcohol use. Nearly 70 % of patients admitted for detoxi-
fication report sleep problems prior to admission, and 
80 % of those who report sleep problems relate them to 
their substance use [169]. The association between sub-
stance use and sleep problems appears to be bidirectional 
[105, 110], with sleep problems increasing risk for devel-
oping substance use disorders [31, 89, 210], and acute 
and chronic substance use leading to acute and chronic 
problems with sleep [44, 47, 89, 97, 104, 138, 156, 168]. 
Evidence also indicates that long-term abstinence from 
chronic substance use can reverse some sleep problems 
[13, 37]. This paper aims to explore and clarify the strong 
yet not entirely understood connection between abnor-
malities in sleep and substance use. By improving our 
understanding of sleep disorders that either predispose 
to substance use or are the result of chronic substance 
use, we may be better able to prevent and treat substance 
use disorders.
Understanding the sleep problems related to sub-
stance use disorders requires characterizing them both 
subjectively and objectively, while considering how sleep 
responds to periods of use and abstinence. This review 
will describe such research with regard to alcohol, can-
nabis, cocaine, and opioids. In addition, this review will 
discuss evidence that sleep abnormalities predict use and 
relapse, and that sleep abnormalities can be modulated 
to improve clinical outcome. This paper will also review 
potential pharmacological agents that modulate sleep. 
Psychotherapy options, albeit evidence-based and of 
clear clinical value, will not be discussed in this review as 
these are addressed elsewhere [15, 110].
Methods
This is a narrative, non-systematic review of clinical trials 
conducted in humans. For the literature search, Pubmed, 
Ovid Medline, and Web of Science databases were used. 
For each drug (e.g., alcohol, cannabis/marijuana, cocaine, 
and opioids/heroin) keywords included terms describing 
abnormal/pathological use (e.g., alcohol use disorders, 
alcohol abuse, alcohol dependence, and alcohol addic-
tion, etc.) combined with terms referring to sleep or sleep 
abnormalities [e.g., sleep, insomnia, polysomnography, 
total sleep time, slow-wave sleep, rapid eye movement 
(REM) sleep, sleep latency, REM latency; these terms are 
defined in Table 1]. In addition to extracting data avail-
able in each of the retrieved articles, reference lists from 
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each retrieved article were examined to identify articles 
missed by the initial search. For each drug, the available 
literature on subjective measurements, objective meas-
urements, the relationship between subjective and objec-
tive measurements, clinical and laboratory correlates of 




Alcohol is widely used as a sleep-promoting agent. How-
ever, as the consumption of alcohol becomes chronic, 
alcohol has less of an hypnotic effect [196]. Significant, 
self-reported sleep problems are highly prevalent among 
alcohol users with rates of clinical insomnia between 
approximately 35 and 70  % depending on the setting 
and stage of use, among other parameters [35, 48]. These 
rates are substantially higher than those observed in the 
general population (i.e.  ~15 to 30  %) [32]. Complaints 
typically include difficulty falling asleep, frequent awak-
enings, daytime sleepiness, and abnormal sleep quality 
[15, 34, 196], but could also include hypersomnia [196]. 
Notably, sleep complaints associated with alcohol use dis-
orders are one of the most refractory problems to resolve 
[34, 69, 82], and insomnia is the most frequent complaint 
among alcoholics after they stop drinking [132].
Objective measurements
Objective measurement of sleep in persons with alcohol 
use disorders confirms self-reported sleep problems in 
many respects, and provides additional insight into the 
nature of the underlying sleep abnormalities.
Sleep latency (SL)
Although it is known that alcohol can decrease sleep 
latency when consumed by healthy persons [124], 
chronic use leads to increased sleep latency, consist-
ent with individual self-report. Published studies show 
that SL is prolonged during periods of drinking [9, 33, 
85, 199, 221], during acute withdrawal (e.g., weeks 
1 and 2 of abstinence) [9, 33, 85, 199, 221], and dur-
ing post-acute withdrawal (e.g., weeks 2 through 8) 
[33], (Table  2) with evidence for sleep latency pro-
longation in inpatient and outpatient settings (e.g., 
[83, 123, 183]), and when controlled for age and sex, 
among other variables [26]. After the second month of 
abstinence, sleep latency may still be increased [213], 
or normalized [174], with evidence for normalization 
also present after five [69] and 9 months of abstinence 
[213].
Total sleep time (TST)
Congruent with increased sleep latency, total sleep time 
is reduced in persons with alcohol use disorders during 
periods of drinking, acute withdrawal, and post-acute 
withdrawal [33, 85, 86, 199, 221], with very few excep-
tions [9]. Numerous studies examining total sleep time 
from 2 to 4 weeks of abstinence document reduced sleep 
time compared to healthy controls [69, 83, 183] (Table 2). 
Reduced total sleep time has also been observed in study 
Table 1 Sleep terminology
Homeostatic sleep drive The drive to sleep that progressively builds with continued wakefulness
Insomnia A sleep disorder in which the quantity or quality of sleep is less than desired, usually characterized by difficulty fall-
ing or staying asleep, or waking too early, and experiencing daytime consequences of reduced sleep
Polysomnography (PSG) A technique that records brain activity, eye movements, and muscle tone in order to study sleep and diagnose 
sleep disorders
Rapid eye movement (REM) sleep The phase of sleep characterized by conjugate eye movements, paralysis of other muscles, and brain activity that is 
most similar to wakefulness
REM density The frequency of rapid eye movements occurring during REM sleep. REM density increases over the course of the 
sleep period and is greatest when homeostatic sleep drive (sleep pressure) is lowest
REM latency The amount of time from the onset of sleep to the onset of REM sleep
REM rebound The characteristic increase in REM sleep after REM sleep deprivation
Self-administration A method involving research participants administering a substance to themselves under observation in a clinical 
setting
Sleep architecture The structure of sleep, including non-REM (stages N1, N2, and N3) and REM (stage R) sleep
Sleep efficiency (SE) The percent of time in bed spent sleeping, calculated as total sleep time divided by time in bed
Sleep fragmentation Disruption in sleep characterized by awakenings and transitions to light (stage N1) sleep from deeper sleep
Sleep latency (SL) The amount of time from lights out to sleep onset
Slow-wave sleep (SWS) Also known as stage N3 sleep, slow wave sleep is characterized by low frequency and high amplitude waves
Total sleep time (TST) The amount of sleep in one complete episode of sleeping, usually reported in minutes
Wake after sleep onset (WASO) The amount of time awake after the onset of sleep and before final wakening
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designs that control for age and sex, among other vari-
ables [26].
Total sleep time in persons with alcohol use disorder 
may improve after sustained abstinence. For instance, 
one group found decreased yet gradually improving 
TST among alcoholic subjects after 19  weeks, 14, and 
27 months of abstinence (312, 335, and 349 min, respec-
tively) [69]. Another study examined TST after 1–2 years 
of abstinence and found no abnormalities among subjects 
recruited from Alcoholics Anonymous vis-à-vis controls 
[2].
Slow‑wave sleep (SWS)
Considerable evidence points to deficits in slow wave 
sleep time (i.e. stage 3 and stage 4 sleep, or stage N3 sleep 
in the newer nomenclature) or slow-wave sleep activ-
ity (i.e. EEG spectral power in the slow wave frequency 
range) in persons with alcohol use disorders [33]. Most of 
this evidence comes from studies reporting results from 
the first few weeks of abstinence, including acute with-
drawal [196], subacute withdrawal (i.e. days 8 and 12); 
[106] (Table 2), and beyond [26, 69, 83, 127].
Although there is evidence that SWS deficits are recov-
ered with prolonged abstinence, current literature does 
not provide a definitive time frame for these improve-
ments, yet does suggest that it may be between 3 and 
14 months [33] or longer. While one study found no dif-
ference between alcohol users and controls at 25  days 
abstinent [183], other studies found that SWS had 
improved at 3  months, and normalized at 9  months of 
abstinence [196]. In contrast, other studies have reported 
persistent deficits [69] or a trend toward deficits [2] after 
as long as 1–2 years of abstinence, with complete recov-
ery occurring only after 1–4 years of abstinence [199].
Intriguingly, acute alcohol use has been shown to 
reverse the chronic slow wave sleep deficits observed 
in chronic alcohol users [33, 86]. Given the widespread 
importance of slow-wave sleep [65] in factors including 
sleep continuity, learning, and memory, as well as other 
types of cognitive performance, the deficits associated 
with chronic use (and their reversal with acute use of 
alcohol) suggests the particular importance of slow-wave 
sleep in alcohol use disorders. More specifically, as the 
brain processes that underlie the generation of these slow 
waves appear to be chronically altered by chronic alco-
hol use, and to be temporarily restored by acute use, this 
chronic alteration is implicated as a potential factor in 
relapse.
Rapid eye movement (REM)
For both persons without alcohol use disorders (AUD) 
[118, 219] and individuals with alcohol use disorders, 
drinking alcohol acutely suppresses REM sleep time. For 
persons with AUD, REM rebound occurs several days 
later [33]. An early study of sleep in persons with AUD 
who were exposed to alcohol found that REM sleep, 
measured as a percentage of total sleep time (REM%) 
was less, relative to baseline, after 2–3  days of absti-
nence, but then rebounded after 5–6 days of abstinence 
[7]. This rebound in REM sleep has been explained as 
reflecting both an increased number of REM periods as 
well as shorter intervals between each REM cycle [196]. 
REM rebound has been documented after 2–3 weeks of 
abstinence [26, 69, 83, 127], and even after 27 months of 
abstinence [69].
Notwithstanding the above findings, the literature 
on alcohol and REM sleep has some inconsistencies 
(Table  2). For example, a meta-analysis examined six 
studies that did not consider covariates and four stud-
ies that controlled for variables such as age and sex 
(all participants abstinent for at least 3  weeks). Even 
though the analyses among all subjects showed no dif-
ferences in REM measured as the percentage of total 
sleep (REM%), the analyses did find increased REM% in 
persons with AUD compared to controls when control-
ling for some variables [26]. Other studies have found 
Table 2 Objective sleep changes during early and late abstinence, in comparison to healthy sleepers
Early Abs Early Abstinence or acute withdrawal
Late Abs Late Abstinence or subacute withdrawal
? Insufficient data or conflicting results across studies
Alcohol Cocaine Cannabis Opioids
Early Abs Late Abs Early Abs Late Abs Early Abs Late Abs Early Abs Late Abs
Sleep latency ? ↑ ? ↑ ↑ ? ↑ ↑
Total sleep time ? ↓ ? ↓ ↓ ↓ ↓ ↓
Slow wave sleep ? ↓ ↓ ↓ ↓ ? ↓ ↓
REM sleep ? ? ? ↓ ↑ ↓ ↓ ?
REM latency ? ? ↓ ? ↓ ? ↑ ?
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no difference in REM% between chronic alcohol users 
and normal controls in the second [106] and third [83] 
week of abstinence. Additionally, supporting the finding 
of no difference in REM between chronic alcohol users 
and controls, a study examining REM time after 4 weeks 
of abstinence found no difference between subjects with 
AUD and normal controls [183]. Another discrepancyap-
pears in the form of a study that found REM% among 
participants with AUD to be reduced after 12  weeks of 
abstinence in comparison with REM% after 4  weeks of 
abstinence, arguing against a lasting REM rebound [171].
Possibly contributing to differences in REM sleep find-
ings are variations across studies in how control partici-
pants were recruited [183] and how well these control 
subjects matched the subjects with AUD in terms of 
measures relevant to sleep architecture such as age. An 
example of this is a meta-analysis exhibiting different 
results depending on whether authors controlled for those 
variables or not [26]. Another factor could be that several 
studies report REM%, thus, the numbers are also a reflec-
tion of not one, but two sleep architecture measurements 
(e.g., REM and TST) that are both undergoing dynamic 
changes as subjects with AUD progress in abstinence [69].
REM latency
Data on REM latency in persons with alcohol use disor-
ders is more limited but also show some discrepancies. 
For instance, while some studies report that REM latency 
is decreased during the second week of abstinence [69, 
106], as well as up to two years later [69], other studies do 
not report differences in REM latency [26, 32] (Table 2). 
One potential explanation for the inconsistencies in this 
measure could lie in the heterogeneity of subjects with 
AUD with regard to co-occurring conditions like depres-
sion. Supporting this idea is the finding that AUD sub-
jects with secondary depression exhibit shorter REM 
latency compared to AUD subjects who do not have sec-
ondary depression [83].
Objective sleep quality or consolidation of sleep
Several studies examining sleep in persons with alcohol 
use disorders also reported data on fragmentation of 
sleep. Sleep fragmentation reflects awakenings or switch-
ing from a deeper to a lighter stage of sleep, and is meas-
ured by the number of switches from one stage of sleep 
to another, the number of awakenings, and the time spent 
awake after sleep onset. The measurements of sleep frag-
mentation provide some insight into the objective qual-
ity of sleep. Results from these studies show consistent 
deficiencies in objective sleep quality, with an increase in 
sleep stage switches compared to healthy controls from 
day 2 of abstinence to as far out as 1–2  years of absti-
nence [2, 106, 196].
Sleep stage switches, number of awakenings and time 
awake after sleep onset were also found to be increased 
on the second night of abstinence compared to the sec-
ond week of abstinence, which suggests greater abnor-
malities in objective sleep quality occur during the 
withdrawal period [106]. In addition, increased sleep 
fragmentation was observed after 3 and 9  months of 
abstinence [196].
Relationship between subjective and objective outcomes
Although there is limited published data on the relation-
ship between subjective and objective sleep measurement 
in persons with alcohol use disorders, one group stud-
ied 172 individuals with alcohol use disorders of whom 
104 had insomnia as determined by the Sleep Disorders 
Questionnaire [35]. They found that participants with 
baseline insomnia had longer sleep latency and lower 
sleep efficiency at an average of approximately 1 month 
abstinent than those without, suggesting a correspond-
ence between self-report and objective measurement.
Clinical and laboratory correlates of subjective 
and objective sleep outcomes
In a small study, increased sleep latency associated with 
chronic alcohol use was linked with lower overall mela-
tonin levels as well as with a delay in the onset and peak 
of melatonin [123]. A much larger study found an asso-
ciation between increased sleep latency and decreased 
sleep efficiency among persons with AUD and sleep dis-
order breathing [6].
In patients with AUD, insomnia is also correlated with 
amount of alcohol use [22], severity of alcohol use disor-
der [35], and self-report of alcohol use as a sleep aid [35]. 
An association between insomnia and severity of self-
reported depression symptoms has also been recognized 
[35].
Relationship between subjective measurements and clinical 
outcomes
Several studies among alcohol AUD subjects have docu-
mented the relationship between self-reported insomnia 
and clinical outcomes. These studies examined the effects 
of 1 week of abstinence while undergoing inpatient admis-
sion (e.g., subjects who self-reported insomnia during this 
week had higher likelihood of choosing to drink as part 
of a subsequent inpatient period in which this option was 
allowed) [182], and showed similar results after following 
subjects for 3 months post-detoxification (e.g., compared 
to subjects who did not relapse during this period, sub-
jects who did relapse were more likely to answer “yes” to 
the statement, “It takes me a long time to fall asleep” from 
the Nottingham Health Profile [NHP] or, “I sleep badly at 
night,” as part of their baseline assessments) [76], or after 
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following subjects for 5  months (e.g., having insomnia 
based on the Sleep Disorders Questionnaire after 2 weeks 
of abstinence was a predictor of relapse). Also, subjects 
who relapsed after 5 months had more baseline complaints 
of difficulties falling asleep and abnormal sleep than the 
group who did not relapse [34, 35].
Relationship between objective measurements and clinical 
outcomes
Mixed findings implicate objective sleep measurements 
as predictors of clinical outcomes in AUD. For example, 
increased sleep latency measured within the first 2 weeks 
of inpatient admission increased the odds of relapse to 
alcohol use within the following 5 months [34]. Similarly, 
increased sleep latency and decreased sleep efficiency 
after 16  days and 19  weeks of abstinence were associ-
ated with lower rates of abstinence at 14  months [69]. 
However, one study found no difference in sleep latency 
at 5  days abstinent between persons who subsequently 
relapsed and those who remained abstinent [82].
Two studies have reported a connection between slow-
wave sleep and clinical measures in persons with AUD. 
Slow-wave sleep time was inversely correlated to the maxi-
mum number of withdrawal symptoms reported during 
subacute withdrawal (8–32  days of abstinence) [83], and 
lower percent of stage 4 NREM sleep was associated with 
relapse [34]. However, another study found no difference 
in slow-wave sleep between relapsers and abstainers [82].
Similar to clinical studies examining sleep latency and 
SWS, REM sleep measurements appear to be impor-
tant in clinical outcomes, but with conflicting results. 
The differences observed here might be consistent with 
the differences in the measurement of REM sleep in per-
sons with AUD described above. For instance, while one 
study indicated a positive correlation between low REM% 
with response rate in a button-press task to obtain an 
alcoholic drink [8], Gillin et al. showed increased REM% 
and shorter REM latency upon admission and upon dis-
charge from a four-week admission among relapsers in 
comparison with abstainers [82]. Another study showed 
that increased REM latency decreased the odds of relaps-
ing [34], and one study found no connection between 
REM latency measured at 19  weeks of abstinence and 
subsequent relapse [69]. The variation in results regard-
ing REM sleep may be due to the different effect that 
acute and chronic use, have on REM sleep, and be due 
to changes in REM sleep as the number of days absti-
nent increases. Another important consideration is that 
achieving long periods of abstinence (e.g., like 19 weeks) 
is in general a good predictor of abstinence and does so 
to a much greater degree than the predictive qualities 
of other physiological measurements obtained early in 
abstinence.
Pharmacotherapy options targeting sleep abnormalities
Because of the profound effects of chronic alcohol use 
and sleep and the apparent connection between sleep 
measures and clinical outcome, several studies have 
examined the role of sleep-promoting medications in 
treating persons with AUD (for review see [119]). In dou-
ble-blind, placebo-controlled and other trials, gabapen-
tin has been studied with largely [112, 136, 137] but not 
entirely [39] positive results. These studies suggest that 
gabapentin may promote both sleep outcomes and absti-
nence [137] in persons with alcohol use disorders.
Given the suggestion that melatonin levels are 
decreased in alcoholics [177, 212], the melatonin receptor 
agonists ramelteon and agomelatine have been examined 
in case series. Among patients who had been abstinent 
for 2–13 weeks, ramelteon was associated with decreased 
scores on the Insomnia Severity Index (ISI),decreased 
sleep latency, and increased total sleep time measured 
by actigraphy [36]. Similarly, agomelatine was associated 
with improved sleep as measured by the Pittsburgh Sleep 
Quality Index after 6 weeks [87].
Another potential pharmacotherapeutic agent that has 
been studied in this population is quetiapine. In a dou-
ble-blind, placebo-controlled trial, quetiapine was associ-
ated with improvements in time awake after sleep onset 
and subjective insomnia [53]. In addition, a retrospective 
study showed an improvement on the insomnia subscale 
of the HAM-D [173] with quetiapine. The effect of que-
tiapine on alcohol-related clinical outcomes has been 
mixed, with evidence for improvement in abstinence 
rates in one study [142], and increased risk of re-hospital-
ization in another [143].
Trazodone is widely prescribed as a sleep aid in per-
sons with addictions because of its lack of addictive 
potential. Although studies of trazodone in persons with 
AUD has shown benefits in sleep measurements [125] in 
a large, placebo-controlled trial, those benefits on sleep 
quality did not result in clinical improvement, but rather 
trazodone was associated with less abstinence during 
treatment and an increase in drinking after cessation 
of treatment [79]. Findings like these suggest that the 
relationship between sleep physiology and alcohol use 
and relapse is not simple. Rather, treatments directed at 
sleep that improve qualitative sleep but do not address 
the underlying physiological changes associated with 
chronic alcohol use may not be expected to promote 
abstinence.
Unlike trazodone, the popular benzodiazepine and 
benzodiazepine-like agents are often avoided in per-
sons with alcohol use disorders because of their addic-
tive potential and the increased risk of toxicity or 
overdose when these medications are mixed with alco-
hol [16, 90].
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Cannabis
Subjective measurements
Like alcohol, cannabis may improve subjective sleep 
complaints [56], particularly when used over short peri-
ods of time. For instance; in studies using self-report 
questionnaires (e.g., Leeds Sleep Evaluation Question-
naire) participants report greater ease in getting to sleep 
[50]. However, like alcohol, chronic cannabis use is asso-
ciated with negative subjective effects on sleep that are 
manifested most prominently during withdrawal. Nota-
bly, these subjective effects are present during discon-
tinuation of cannabis use even among persons who were 
exposed to low dosages [97], and are common among 
regular users [61, 188]. Symptoms reported include sleep 
difficulties [61] such as strange dreams, insomnia, and 
poor sleep quality. Such symptoms occur in anywhere 
from 32 % [58] to 76 % [27, 222] of persons experiencing 
withdrawal. These studies have been conducted in both 
the inpatient (residential) [61, 97, 98] and outpatient lev-
els of care [42, 44], and in studies with as many as 450 
participants [222]. Placebo-controlled studies have exam-
ined what happens after discontinuation of oral THC use 
[97] or after discontinuation of smoked marijuana [98]. 
Regardless of design, studies of the effects of chronic use 
have consistently shown reliable and significant changes 
in subjective reports of sleep during abstinence in com-
parison to baseline [42].
Among the problems with sleep in chronic cannabis 
users is the presence of strange dreams [44]. Such dreams 
typically begin 1–3 days after cannabis discontinuation—
when sleep quality is particularly poor [42, 44, 195], peak 
after 2–6 days, and last 4–14 days [44], coincident with 
other subjective sleep complaints. However, large stud-
ies have found sleep difficulties lasting for longer periods, 
such 43 days [58], and strange dreams in particular last-
ing for as long as 45 days [44]. Returning to cannabis use 
(or using alcohol or other sedatives) to promote sleep is 
commonly observed [58].
However, the sleep-promoting effect of cannabis is 
lessened in the chronic user compared to naïve users 
[50–52, 91], while the negative effects of cannabis on 
sleep intensify with chronic use as noted above. This 
scenario leaves the chronic user in a potential catch-22: 
heavier use of cannabis may be necessary to receive its 
subjective sleep-promoting effects in the chronic user, 
but at the same time this increased use contributes to 
worsening overall sleep and therefore leads to continued 
and greater use.
Objective measurements
Studies examining the effect of cannabis on objec-
tive sleep measurements obtained either by an experi-
enced observer rating sleep by polysomnography (PSG) 
largely confirm the subjective reports. For instance, an 
observer-rated study showed that administration of 10, 
20, or 30 mg of THC decreased total time to fall asleep 
[60], and a PSG study showed both shorter sleep latency 
(SL) [150], and decreased time awake after sleep onset 
(WASO) [160]. However, other studies have not observed 
a decrease in sleep latency or wake time after sleep onset 
[75]. One possible explanation for the difference in find-
ings may be related to disparate effects of THC (sleep 
promoting) and cannabidiol (a non-euphorigenic can-
nabinoid preferred in some medical preparations), which 
may increase alertness [150].
Several studies of PSG-measured sleep report increased 
SWS [25, 75], decreased REM sleep [74, 75, 160], and 
decreased REM density (e.g., number of eye movements 
during REM sleep) [74, 75]. However, this pattern is not 
always replicated [150].
In chronic users of cannabis, the effects of cannabis on 
objectively measured sleep are notably different. With 
chronic use, individuals develop tolerance to most of 
the effects observed in naïve users, including its sleep-
inducing effects and slow-wave sleep enhancement [25, 
78, 111, 163]. Sleep efficiency is similarly unimproved 
[163] or worsens [111]. The tolerance to REM sleep 
changes, however, appears to be relatively muted [75]. 
However, no consensus exists with respect to REM time 
and studies have reported decreased, no change [163], or 
increased [111] REM time.
PSG studies of cannabis withdrawal have demon-
strated increases in sleep onset latency and wakefulness 
after sleep onset [27, 28, 75, 77, 78, 175] (Table 2). Total 
sleep time, sleep efficiency, and slow-wave sleep time 
is reduced [1, 27, 28, 75, 78] (Table  1), and REM sleep 
is increased (REM rebound) [74, 75, 77, 108, 160, 175]. 
Shorter REM latency has also been reported [27, 77].
Changes in the objective PSG measurements during 
withdrawal can start as soon as the first night of absti-
nence (e.g., the decrease in SWS time [74]). Changes 
during withdrawal are more noticeable among heavy mar-
ijuana users (marijuana use ≥5 times per week over the 
past 3 months) [27]. With continued abstinence, TST, SE, 
and amount of REM sleep decline (Table 2), while WASO 
increases. These disturbances progress over the first 
2 weeks of abstinence [28, 44, 120] and persist for more 
than 45 days into a marijuana abstinence period [44].
There are conflicting reports with regard to REM 
sleep in sustained abstinence. Initially it appears that 
REM sleep time increases/rebounds early in abstinence, 
but decreases as abstinence progresses [28] (Table  2). 
The reason for this continued worsening of sleep with 
decreasing REM sleep during abstinence is unclear, but 
could reflect a pre-existing, underlying sleep problem 
and/or the long-term effects of chronic use.
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Relationship between subjective and objective outcomes
As noted above, the desirable effects of cannabis on sleep 
are reported less frequently in chronic cannabis users 
compared to naïve users [91], Chronic users also report 
difficulty sleeping and strange dreams among other 
symptoms associated with abstinence [11, 28, 43, 58, 175, 
194]. These subjective findings have been correlated to 
longer sleep onset latency, reduced slow-wave sleep, and 
REM rebound observed in PSG studies [27, 198].
Clinical and laboratory correlates of subjective 
and objective sleep outcomes
Sleep difficulties appear to be a predisposing factor for 
cannabis use, and baseline sleep problems are a signifi-
cant predictor of later cannabis use, doubling the risk of 
future use [139, 155, 166, 211, 214]. This latter finding has 
led some to describe cannabis use as “coping oriented 
use” [21].
The sleep disturbances encountered in marijuana with-
drawal may play a crucial role in treatment outcomes. 
Higher rates of relapse have been correlated with sleep 
problems and other withdrawal symptoms [43]. In a 
study focused on military veterans, Babson et al. showed 
that poor sleep quality prior to the quit attempt was a 
predictor of higher rates of later cannabis use [19–21]. 
Similarly, poor sleep quality during abstinence also con-
tributes to relapse [44, 46, 195]. Evidence from a limited 
number of studies suggests that objective findings, like 
increased periodic limb movements during abstinence, 
are correlated with quantity and duration of cannabis use 
[28].
Pharmacotherapy options targeting sleep abnormalities
Sleep disturbances associated with withdrawal improve 
with oral administration of THC or resumption of can-
nabis use [42, 44, 45, 95, 97, 108]. THC exerts a dose-
dependent effect in reducing withdrawal symptoms [45], 
but as noted above, the beneficial effects of THC on sleep 
diminish with chronic use, and chronic use leads to more 
severe problems with sleep.
Haney et al. found the greatest benefit regarding sleep 
symptoms and relapse using combination therapy with 
lofexidine (an alpha-2 agonist) and oral THC. However 
they did not report any benefit from 10 days of oral THC 
alone [94]. Nabilone, a FDA-approved synthetic analog 
of THC, has the potential to reverse withdrawal-related 
irritability and disruptions in sleep, and promotes absti-
nence [92]. Nabiximols, a synthetic combination of THC 
and cannabidiol has a non-significant positive effect on 
these parameters [10].
The use of valproic acid resulted in no benefit and even 
some worsening of symptoms in chronic cannabis users 
[95, 128]. No definitive benefits have been reported with 
Lithium [107], nefazodone [96], or bupropion [49, 99].
Subjective and/or objective sleep parameters have 
been shown to improve with the use of zolpidem [195], 
mirtazapine [93], gabapentin [135], and quetiapine [57], 




Withdrawal from cocaine is characterized by numerous 
subjective complaints, including sleep and sleep-related 
complaints. The first several days to 1 week after cocaine 
cessation are characterized by sleep disturbances, hyper-
somnia, bad dreams, depressed mood, psychomotor agi-
tation and retardation, fatigue, and increased appetite 
[38, 59, 80]. With continued abstinence, however, there is 
subjective improvement of sleep as well as improvements 
in other cocaine withdrawal measures [209], with appar-
ent normalization of subjective sleep over the course of 
several weeks [80].
Numerous studies have indicated an improvement 
in self-reported sleep quality over the first few weeks of 
abstinence [13, 55, 81, 138, 147, 148, 153, 172, 209], with 
improvements in measures such as overall sleep qual-
ity, daytime alertness, concentration/confusion, depth of 
sleep, and energy/fatigue. However, the possibility that 
such improvements may be related to acclimation to a 
new environment (e.g., the treatment setting [209]) and 
not actually reflect good sleep relative to healthy persons 
[55] has been raised. Possibly providing some answers 
to these questions, a laboratory study that included self-
administration of cocaine either early or late in a 3-week 
period of abstinence showed that subjective sleep quality 
was at its worst in the first few days following cocaine use 
and improved with continued abstinence [148]. In addi-
tion, whereas chronic cocaine users show impairment in 
self-reported but quasi-objective sleep measurement like 
the Pittsburgh Sleep Quality Index (PSQI), visual analog 
scale ratings of subjective sleep quality in the third week 
of abstinence are no different from healthy sleepers [147]. 
Hence there is evidence that chronic cocaine users have 
chronically impaired sleep as measured by instruments 
like the PSQI, that self-reported sleep quality improves 
with continued abstinence, and that self-reported sleep 
quality after an extended period of abstinence is similar 
to that in healthy sleepers. However, this last finding may 
only show that chronic cocaine users’ intrinsic scale for 
self-report of sleep quality is different from healthy sleep-
ers, with ‘good’ subjective sleep in chronic cocaine users 
seemingly good only in comparison with the much worse 
sleep experience they have at other times.
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Objective measurements
Although self-reported sleep improves following the ini-
tial withdrawal from cocaine, polysomnographic findings 
have consistently shown deterioration in sleep to insom-
nia-like levels in the same period [13, 81, 104, 121, 138, 
145, 148, 152, 192]. The co-occurring deterioration in 
PSG-measured sleep and improvement in self-reported 
sleep quality was termed ‘occult insomnia,’ as poor sleep 
as measured by PSG was associated with poor perfor-
mance on sleep-dependent learning and other cognitive 
tasks [148, 149]. These findings suggest that the PSG-
measured deterioration in sleep and not the subjective 
improvement in sleep better reflects what is happening 
during abstinence from chronic cocaine use, and sup-
ports the notion that the intrinsic, subjective scale used 
by chronic cocaine users to report sleep quality is altered 
relative to healthy persons.
Sleep latency
Acute cocaine administration can increase sleep latency 
[104, 162, 207], but the first few days of abstinence from 
cocaine in chronic users is associated with short sleep 
latencies relative to later in abstinence [81, 121, 138, 
148, 153, 192], when sleep latency may be as long as 
30–60 min or more (Table 2).
Total sleep time
Total sleep time during abstinence is reduced in chronic 
cocaine users [147] but appears to be at its greatest 
sometime in the early abstinence period (first week 
of abstinence) in laboratory studies including cocaine 
self-administration [148]. Total sleep time decreases 
with continued abstinence (Table  2), however [81, 104, 
121, 138, 147–149, 153, 162, 192, 207], with total sleep 
times around the third week of abstinence as low as 
300–330  min despite prohibitions against daytime nap-
ping and the opportunity to sleep 8  h or more. Sleep 
efficiency follows a similar pattern, with insomnia-like 
levels apparent in the third week of abstinence [153]. 
Limited evidence suggests that chronic cocaine users able 
to maintain outpatient abstinence for as long as 54 days 
show some improvement in total sleep time [13].
Slow‑wave sleep
Chronic cocaine users appear to have dramatically 
diminished slow-wave sleep time relative to age-matched 
healthy sleepers [13, 147] (Table  2). More limited evi-
dence suggests that slow-wave activity is increased by 
cocaine self-administration earlier in the day, with a 
subsequent loss of slow-wave activity in the first several 
days of abstinence followed by a rebound over the next 
2  weeks of abstinence [148]. More substantial evidence 
indicates that slow-wave sleep time increases modestly 
from the first to the third week of abstinence [138], but at 
3 weeks of abstinence is still 50 % less than age-matched 
healthy sleepers [13]. This deficit in slow-wave sleep gen-
eration is associated with impaired slow-wave sleep spe-
cific, sleep-dependent learning [149], and is consistent 
with or more profound than similar findings in chronic 
users of alcohol, cannabis, other stimulants, and heroin 
[25, 27, 175, 192] suggesting an abnormality in sleep 
homeostasis [145] that may be common to chronic, regu-
lar use of addictive substances.
Rem
Cocaine administration acutely suppresses REM sleep 
[104, 162, 207], with a subsequent rebound evident as 
an increase in REM sleep time and/or percent of total 
sleep time spent in REM (REM%), and a decrease in REM 
latency [81, 104, 121, 149, 153, 192, 207]. However, in 
chronic cocaine users, REM sleep decreases following the 
rebound, with low REM times observed during the sec-
ond and third weeks of abstinence [13, 104, 138, 147, 149, 
153, 192] (Table  2). This diminished REM sleep time is 
associated with cognitive consequences like poor proce-
dural learning [149], suggesting an abnormality of REM 
homeostasis during abstinence from chronic use. Con-
sistent with this idea is the observation that REM latency 
is higher in the third week of abstinence relative to the 
first [149] and at 3 weeks abstinence does not differ sub-
stantially from healthy sleepers [147] (Table  2), despite 
low REM sleep time.
Relationship between subjective and objective outcomes
What is now clearly shown to be a mismatch in subjec-
tive and objective experience during acute and suba-
cute abstinence was once perceived as an inconsistency 
[104, 153]. One possible cause for the mismatch may be 
dysregulation of the homeostatic sleep drive in chronic 
cocaine users, wherein the ‘sleepiness’ and other nega-
tive effects of increased wakefulness are not experi-
enced subjectively [148]. Additionally, or alternatively, 
the rebound in delta power after acute withdrawal [148], 
despite poor sleep and decreased slow-wave sleep time, 
may improve the subjective experience of sleep quality 
[122, 148]. The poor subjective experience in acute with-
drawal may also be related to the decreased REM latency 
and increased REM sleep time, leading to increased 
dreaming [38, 59] and correlated with symptoms of 
withdrawal [13].
Clinical and laboratory correlates of subjective 
and objective sleep outcomes
Cognitive correlates of sleep outcomes
Chronic cocaine use is associated with various cog-
nitive performance deficits (e.g., see [152]) that may 
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predict treatment retention and other outcomes [3–5]. 
As described briefly above, poor sleep associated with 
abstinence from chronic use may contribute to poor 
cognitive performance including decreased attention or 
vigilance [148, 149, 152]. The most direct associations 
between poor sleep and cognitive deficits, however, are 
observed in sleep-dependent procedural learning. In 
such tasks, overnight learning is strongly correlated with 
objective sleep measurement, such as slow-wave sleep 
time [189], REM time [189], and stage 2 (N2) sleep time 
(M. P. [202]. In chronic cocaine users, similar correlations 
are present; in nights with relatively normal sleep, normal 
sleep-dependent learning takes place, but in nights with 
impaired sleep, such learning is similarly impaired [148, 
149]. Hence, sleep abnormalities associated with absti-
nence from chronic cocaine use may be responsible for 
significant impairment in normal, sleep-dependent learn-
ing, as well as more immediate cognitive function like 
attention. Intriguingly, cocaine administration is associ-
ated with temporary reversal of these deficits [148, 149, 
152], further implicating such deficits in risk for relapse.
Relationship between objective measurements and clinical 
outcomes
Recent evidence supports the assertion that poor sleep 
associated with abstinence from cocaine not only impairs 
cognitive performance, but also contributes to increased 
cocaine use or relapse [13]. In this study, the homeostatic 
response to continued abstinence (which was measured 
as change in slow-wave sleep time from the first week 
of abstinence to the second or third week) predicted 
the amount of cocaine self-administered in a laboratory 
experiment and clinical outcome in a clinical trial. In 
addition, REM sleep time and total sleep time during the 
third week of abstinence predicted the amount of cocaine 
self-administered. In all cases, improvements in sleep 
were associated with less self-administration or better 
clinical outcome.
Pharmacotherapy options targeting sleep abnormalities
Although several medications such as modafinil, topira-
mate, tiagabine, gaboxadol and vigabatrin [145] have 
been suggested as potential options for targeting the 
sleep abnormalities associated with chronic cocaine use, 
few studies have examined the effects of medications on 
sleep in chronic cocaine users, and several of the sug-
gested medications have potentially significant safety 
issues (i.e. tiagabine, gaboxadol, and vigabatrin). Hypoth-
esizing that the REM rebound associated with initial 
withdrawal from cocaine was caused by dopamine insuf-
ficiency [62], Gillin et al. [81, 82] examined the effect of 
lisuride, a high affinity dopamine D2,3,4 receptor agonist, 
on sleep. While lisuride had the desired effect on REM 
sleep (decreasing REM% and increasing REM latency), it 
had no effects on other withdrawal-related phenomenon 
[81]. In light of the clinical findings in Angarita et al. [13] 
and the effect of prolonged abstinence on REM sleep, it 
seems unlikely that reduction in REM sleep time would 
be beneficial during extended abstinence, but increasing 
REM to normal values could be beneficial.
Another medication that has been tested is tiagabine, 
a GABA-reuptake inhibitor. Since tiagabine is known 
to increase slow-wave sleep time, which is implicated 
in improved cognitive performance in sleep-restricted 
persons [203], it was hypothesized that tiagabine may 
improve slow-wave sleep time in chronic cocaine users 
[146]. While tiagabine had dramatic effects on slow-wave 
sleep time, sleep architecture appeared unnatural, with 
slow-wave sleep occurring throughout the sleep period. 
Additionally, there was no apparent benefit to total sleep 
time, and no consistent benefit in cognitive performance 
[146].
Perhaps the most promising, and most studied medi-
cation to be tested for correcting sleep abnormalities 
related to cocaine is modafinil. A stimulant and cogni-
tive enhancer that appears to act at least partially through 
dopamine transporter blockade, modafinil appears to 
share some important properties with cocaine while 
being a relatively safe medication with low abuse poten-
tial [140]. In chronic cocaine users, modafinil has been 
shown to normalize slow-wave sleep time, as well as 
other sleep parameters [147]. Though effects of modafinil 
on clinical outcome have been mixed (e.g., [12, 63, 64, 
176]), its effects on sleep and its pro-cognitive effects 
position it as the best candidate at present for a viable 
pharmacotherapy for cocaine use disorders.
Opioids
Subjective measurements
Short-term opioid use can cause sedation and daytime 
drowsiness [130, 159, 216, 217]. Dizziness and sleepiness 
are common side effects of opioid pain medications [41, 
109]. With a stable dose, tolerance to the subjective, seda-
tive effects of opioids develops within 2–3 days and some 
studies find that cognition normalizes after that [103, 
129], supporting the notion of tolerance to the sedative 
effects. However, there is also evidence that unpleasant 
sedative effects, decreased alertness and increased reac-
tion time in a variety of cognitive tasks continue to be 
experienced by some patients on a stable dose of narcotic 
medication [23, 24, 54, 181]. These differences in find-
ings may be related to inconsistencies in how the sedative 
effects are defined [217].
Xiao et  al. [215] studied the quality of sleep in per-
sons with heroin use disorder on early methadone main-
tenance therapy (MMT) after a median of 5.4  days of 
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treatment [215]. Patients without pre-existing chronic 
sleep disturbances demonstrated lower ratings of sleep 
(Pittsburgh Sleep Quality Index [PSQI]) and daytime 
sleepiness (Epworth Sleepiness Scale [ESS]) compared to 
healthy sleepers. Oyefeso et al. [151] reported inadequate 
sleep quality and quantity as well as difficulty initiating 
and maintaining sleep in persons with opioid use disor-
ders in early stages of methadone detoxification. Similar 
studies have shown some increased daytime drowsiness 
and below normal sleep measures in this patient popula-
tion [113, 114, 134, 204]. After longer periods of MMT, 
however, there is some degree of tolerance to these 
effects [206], and sleep difficulty is shown to be present 
only in the first 6–12 months of MMT [158, 193].
There is a limited number of reports studying the 
effects of withdrawal and abstinence from chronic opi-
ate use. Asaad et  al. reported insomnia, hypersomno-
lence, increased sleep latency, and reduced sleep duration 
in individuals with opioid use disorder after 3  weeks of 
abstinence [17].
Objective measurements
Sleep architecture in healthy adults can be signifi-
cantly altered even after a single dose of oral opioids 
[67]. Using electroencephalography (EEG) and electro-
myography (EMG), Kay et al. [117] reported that acute 
intoxication with heroin, morphine, or methadone 
resulted in dose-dependent enhancements in arousal 
during sleep–wake periods. Heroin use demonstrated a 
stronger effect particularly on reduction of theta waves 
and REM sleep [117, 204]. Morphine and methadone 
reduce slow-wave sleep and in-crease stage 2 sleep 
[67]. Several studies have shown that acute use of vari-
ous opioids results in increased REM latency [115, 159], 
decreased REM sleep time [113–117, 130, 159, 180], 
increased stage 1 [67, 130, 180] and stage 2 sleep [67], 
and decreased slow-wave sleep [113–117, 159]. Acute 
use of opioids also leads to increased sleep latency [116, 
130], increased wakefulness after sleep onset (WASO) 
[113–117, 130, 159, 215], and concomitant decreases 
in total sleep time (TST) [116, 215] and sleep efficiency 
(SE) [116, 159, 215].
There is a partial tolerance to the effects of opioids with 
some evidence for increased REM sleep time in acute use 
[113, 114, 130], and less pronounced changes in SWS, 
wakefulness, and arousal observed after chronic use. 
However, vocalization during REM sleep, delta bursts, 
and increased daytime sleepiness may be observed in this 
phase [204]. Tolerance to sleep problems is more promi-
nent in MMT [113, 134, 159, 204], with evidence that 
persons in treatment for more than 12  months exhibit 
better recovery sleep following sleep deprivation than 
persons in shorter-term treatment [193].
Nevertheless, abnormal PSG findings are commonly 
reported in chronic opioid users despite development of 
tolerance. These abnormalities include increased sleep 
latency [100, 185], increased awakening [100, 113, 185, 
190], decreased total sleep time [100, 185], and decreased 
sleep efficiency [100, 190]. Slow-wave sleep time [113, 
114, 185, 190] and REM sleep are decreased compared 
to baseline [113, 185, 190, 205], while duration of stage 2 
sleep is increased similar to acute use [190, 205]. Analysis 
of actigraphy data from patients with prescription opioid 
use disorders indicated poor sleep in terms of total sleep 
time, sleep efficiency, sleep latency, total time awake, and 
time spent moving [100].
Several studies have reported changes in patterns of 
sleep with progressive abstinence from opiates. At around 
5–7  days of acute abstinence from chronic heroin use, 
Howe et  al. reported decreased total sleep time, slow-
wave sleep, REM, and stage 2 sleep and increased sleep 
latency, wake after sleep onset, and REM latency com-
pared to healthy sleepers [101] (Table 2). During the first 
3 weeks of abstinence, prolonged sleep latency, decreased 
sleep efficiency, decreased TST, increased arousal index, 
increased stage 1 and 2, and decreased slow-wave sleep 
(SWS) were prominent compared to healthy sleepers [17] 
(Table 2). After 6 weeks and up to 6 months of abstinence 
from methadone, there is a rebound increase in SWS and 
REM time to a higher level than baseline [113, 114, 134].
Relationship between subjective and objective outcomes
Using PSG data, Xiao et  al. showed an inverse relation-
ship between the Epworth Sleepiness Scale (ESS) scores 
and SWS time in patients with heroin use disorder who 
were in early methadone treatment [215]. They reported 
poor initial quality of sleep based on the PSQI scores 
which were significantly correlated with their methadone 
dosages [102]. PSQI score were also found to be signifi-
cantly correlated with average diary-reported sleep time, 
subjective ratings of feeling rested, and PSG sleep effi-
ciency in MMT patients [179]. Overall the high preva-
lence of sleep complaints in this population along with 
documented abnormal objective findings argue that these 
complaints are more likely to be secondary to pathology 
rather than sleep misperception.
Clinical and laboratory correlates of subjective 
and objective sleep outcomes
Opioids and sleep disordered breathing
Acute use of small doses of opioids does not appear 
to significantly increase the risk for increased sleep-
disordered breathing [167, 180]. However, chronic 
opioid use has been associated with several abnormali-
ties including nocturnal oxygen desaturations, abnor-
mal breathing patterns, and Biot’s respiration pattern 
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which ultimately may lead to hypercapnia and hypoxia 
[29, 73, 88, 126, 164, 165, 191, 201, 204, 218]. Chronic 
opioid treatment, particularly with extended release 
preparations is associated with increased risk of cen-
tral and obstructive sleep apneas compared to BMI and 
age-matched controls [73, 88, 141, 190, 200, 201, 204, 
205, 208]. Between 30 and 90 % of patients on chronic 
opioid therapy display signs of central apnea in a dose-
dependent fashion [73, 190, 200, 201, 205]. Several 
studies have indicated that chronic opioid use is an 
independent risk factor for irregular breathing, central 
apneas, and hypopneas [88, 154, 200, 201]. Additional 
abnormalities associated with MMT include sleep-dis-
ordered breathing, lower arterial oxygen saturation and 
higher carbon dioxide concentration [178, 190, 205]. 
There is a positive correlation between the duration of 
MMT and plasma methadone levels with frequency of 
sleep apnea [190, 205].
A multivariate analysis of the relationship between 
demographic factors, mental health and drug use with 
sleep disturbances on 225 MMT patients found that 
depressive and anxious symptoms, greater nicotine use, 
bodily pain, and unemployment were all significant pre-
dictors of poorer global sleep quality [186].
Using PSG, Asaad et al. found that severity of depres-
sion in MMT patients was inversely correlated with SWS. 
They reported that SWS in moderate and severe depres-
sion was significantly lower than in milder depressive 
states. However, duration of opioid abuse or type of opi-
oid did not show a significant correlation with the abnor-
malities in the sleep profile [17].
Relationship between subjective measurements and clinical 
outcomes
Peles et  al. [156] used a logistic regression model and 
showed that a higher methadone dose (defined as greater 
than 120  mg/day) was associated with poor sleep qual-
ity, higher rate of sleep disturbance, more frequent use 
of sleeping medications, and higher rate of daytime dys-
function [156]. However in a later study (2009), they 
found no direct correlation between the methadone dose 
and worse objective and perceived sleep parameters. 
Rather they suggested that duration and intensity of opi-
oid abuse before admission to MMT was directly corre-
lated with sleep abnormalities [157].
Quality of sleep in substance users who are trying to 
quit plays an important role in predicting the treatment 
outcome and poor sleep quality is associated with higher 
risk of relapse [40, 204]. Predictive factors for abstinence 
1 month after detoxification with naltrexone may include 
sleeping problems upon discharge and any changes in 
sleeping problems [66]. In MMT patients, psychiat-
ric disorders, greater nicotine and benzodiazepine use, 
bodily pain, and unemployment are associated with 
poorer global sleep quality [156, 186].
Relationship between objective measurements and clinical 
outcomes
Using PSG, Peles et al. evaluated patients with heroin use 
disorder who were being treated with high and low dose 
methadone [157]. Of the objective sleep indices, percent-
age of non-REM deep sleep (i.e. SWS) inversely corre-
lated with number of years of opioid abuse. They found 
that a lower percentage of SWS and more years of opioid 
abuse were observed in the group who received higher 
methadone dose during MMT.
Positive effects of opioids on sleep
Judicious use of opioid medications might improve pain-
related sleep disorders [14, 30]. Subjective reports of 
improved sleep after pain control with extended-release 
morphine sulfate use to treat patients with chronic hip or 
knee arthritis are backed by objective evidence obtained 
from PSG indicating better sleep quality [170]. Opioids 
have also been used to treat a sleep disorder known as 
periodic limb movement (PLMS), which is often associ-
ated with restless legs syndrome [144].
Pharmacotherapy options targeting sleep abnormalities
Modifiable psychological and medical risk factors asso-
ciated with sleep disturbance should be identified and 
corrected in order to improve quality of life in drug 
treatment. Treatment of sleep disorders among MMT 
patients, particularly in those with psychiatric disorders, 
benzodiazepine abuse, chronic pain, and patients who 
are on high methadone dose is of crucial importance.
Methadone
Methadone maintenance is widely used and a standard 
pharmacotherapy for treating patients with opioid use 
disorders [18, 68, 71, 197, 220]. Chronic methadone use 
is more commonly associated with tolerance to the sleep 
problems compared to other opioids [113, 134, 159, 204]. 
However, more than three-quarters of persons receiv-
ing methadone maintenance therapy (MMT) still report 
sleep complaints [151, 156, 186]. This is complicated by 
the fact that about 50 % of MMT patients report use of 
both illicit drugs and legal medications to help with sleep 
[156, 186]. Methadone and electrostimulation (ES) have 
been used to treat insomnia in the first 30  days of opi-
oid withdrawal [84]. In the first 2  weeks of withdrawal 
patients treated with electrostimulation had shorter sleep 
time and more awakenings than patients receiving meth-
adone. They also found that subjects in the ES group who 
remained in treatment experienced more sleep distur-
bance than those who dropped out prematurely. Overall 
Page 12 of 17Angarita et al. Addict Sci Clin Pract  (2016) 11:9 
methadone and ES were not efficient in treating insomnia 
associated with withdrawal. Stein et  al. tested whether 
trazodone (50 mg/night), one of the most commonly pre-
scribed medications for treatment of insomnia, improved 
sleep among methadone-maintained persons with PSQI 
score of six or higher [187]. They found that trazodone 
did not improve subjective or objective sleep problems in 
this group of patients.
Buprenorphine
Buprenorphine was FDA approved as a pharmacotherapy 
for opioid use disorders in 2002. Buprenorphine has the 
advantage of being available from office-based practices 
[131]. There are limited numbers of studies looking at the 
effect of buprenorphine on sleep. One study suggests that 
buprenorphine is comparable to methadone in improv-
ing sleep quality in patients involved in long-term treat-
ment [133]. In another study, forty-two patients with 
opiate use disorder were treated with either methadone 
or buprenorphine and gradually tapered down over the 
course of 2–3  weeks. Buprenorphine-treated patients 
had 2.5  % lower sleep efficiency and 9  % shorter actual 
sleep time. These significant group differences were 
most pronounced with the lowest doses toward the late 
withdrawal phase [161]. The time course of tapering 
buprenorphine during detoxification might also play a 
role in the quantity of sleep. A randomized controlled 
trial of buprenorphine for detoxification from prescrip-
tion opioid use evaluated sleep time among patients 
assigned to receive 1, 2, and 4-week buprenorphine 
tapers. The 4-week taper group reported significantly less 
loss of sleep compared to the other groups [70].
In a study of 70 patients with chronic opioid use, the 
effect of buprenorphine on sleep disordered breath-
ing was measured polysomnographically [72]. Patients 
in this study tended to be young (mean age of 31.8) and 
non-obese (mean body mass index 24.9 ± 5.9). However, 
treatment with buprenorphine was associated with mild 
to severe sleep-disordered breathing in this population, 
with a substantial rate of associated hypoxemia [72].
Although information on the effect of other medications 
on sleep in chronic opiate users is limited, Srisurapanont 
and Jarusuraisin [184] explored the effect of amitriptyline 
(57.7  ±  12/night) versus lorazepam (2.1  ±  0.5/night) to 
treat insomnia in 27 patients with opioid withdrawal in a 
randomized double-blind study [184]. The Sleep Evalua-
tion Questionnaire and three insomnia items of the Ham-
ilton Depression Rating Scale were used to assess sleep. 
All aspects of sleep (including ease of getting to sleep, per-
ceived quality of sleep, integrity of early morning behavior 
following wakefulness and Hamilton Depression Rating 
Scale insomnia items), except for ease of awakening from 
sleep, were not significantly different in the two treatment 
groups. These findings suggest that apart from the hango-
ver effect, amitriptyline is as effective as lorazepam in the 
treatment of opioid-withdrawal insomnia.
Conclusion
Overwhelming evidence points to chronic alterations in 
sleep from chronic use of addictive substances that may 
be distinct from some or all of the acute effects of those 
substances. Interestingly, the effects of chronic use on 
sleep are similar among both CNS stimulants and depres-
sants. Decreased sleep time, increased sleep latency and 
wake time after sleep onset, and deficiency in slow-wave 
sleep generation appear to be common to chronic use of 
alcohol, cocaine, cannabis, and opiates. REM sleep is also 
affected by acute and chronic use, but may be more sensi-
tive to the pattern or quantity of recent use and time from 
last use, as results vary more among studies. Also linking 
these abnormalities are connections with ongoing use and 
relapse. However, treatment with typical sleep promoting 
agents that increase sleep time or efficiency by increasing 
light sleep may be counterproductive. Agents that address 
deficiency in slow-wave sleep generation and alterations 
in REM sleep may prove to be more useful in addressing 
the connection between chronically-altered sleep physiol-
ogy and ongoing use and relapse, but substantial research 
still needs to be done to explore this possibility.
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